[go: up one dir, main page]

WO2026013165A1 - Association d'un inhibiteur de ship2 et d'un inhibiteur de plk1 destinée à être utilisée dans le traitement du cancer - Google Patents

Association d'un inhibiteur de ship2 et d'un inhibiteur de plk1 destinée à être utilisée dans le traitement du cancer

Info

Publication number
WO2026013165A1
WO2026013165A1 PCT/EP2025/069661 EP2025069661W WO2026013165A1 WO 2026013165 A1 WO2026013165 A1 WO 2026013165A1 EP 2025069661 W EP2025069661 W EP 2025069661W WO 2026013165 A1 WO2026013165 A1 WO 2026013165A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
ship2
cancer
plk1
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/069661
Other languages
English (en)
Inventor
Benjamin Beck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Original Assignee
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB filed Critical Universite Libre de Bruxelles ULB
Publication of WO2026013165A1 publication Critical patent/WO2026013165A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente demande divulgue un inhibiteur de l'inositol 5'-phosphatase 2 (SHIP2) contenant un domaine SH2 et un inhibiteur de Polo-like kinase I (PLK1) destinés à être utilisés en médecine, en particulier dans le traitement du cancer, plus particulièrement du cancer de l'œsophage et du cancer colorectal. Est divulgué en outre un kit d'éléments comprenant un inhibiteur de SHIP2 et un inhibiteur de PLK1 destiné à être utilisé dans le traitement du cancer. Sont divulgués en outre un kit d'éléments comprenant une forme posologique d'un inhibiteur de SHIP2 et une forme posologique d'un inhibiteur de PLK1 et une composition pharmaceutique comprenant un inhibiteur de SHIP2 et un inhibiteur de PLK1.
PCT/EP2025/069661 2024-07-10 2025-07-10 Association d'un inhibiteur de ship2 et d'un inhibiteur de plk1 destinée à être utilisée dans le traitement du cancer Pending WO2026013165A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24187813 2024-07-10
EP24187813.1 2024-07-10

Publications (1)

Publication Number Publication Date
WO2026013165A1 true WO2026013165A1 (fr) 2026-01-15

Family

ID=91898895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/069661 Pending WO2026013165A1 (fr) 2024-07-10 2025-07-10 Association d'un inhibiteur de ship2 et d'un inhibiteur de plk1 destinée à être utilisée dans le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2026013165A1 (fr)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US778A (en) 1838-06-12 Thomas wright
US6372A (en) 1849-04-24 Henei m
WO1999033793A2 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Pro-medicaments qui sont des inhibiteurs de l'aspartyl protease
WO1999033792A2 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments des inhibiteurs de l'aspartyl-transferase
WO1999033795A1 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments de la classe des inhibiteurs d'aspartyle protease
WO1999033815A1 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Derives de sulfamide utilises comme precurseurs d'inhibiteurs de l'aspartyl protease
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6369086B1 (en) 1997-09-05 2002-04-09 Smithkline Beecham Corporation Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
US6372778B1 (en) 1992-09-08 2002-04-16 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6372733B1 (en) 1995-11-01 2002-04-16 Merck & Co., Inc. Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases
WO2014046617A1 (fr) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions et méthodes de traitement du cancer
US20220275368A1 (en) * 2019-08-12 2022-09-01 Interna Technologies B.V. New treatments involving mirna-193a

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US778A (en) 1838-06-12 Thomas wright
US6372A (en) 1849-04-24 Henei m
US6372778B1 (en) 1992-09-08 2002-04-16 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6372733B1 (en) 1995-11-01 2002-04-16 Merck & Co., Inc. Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases
US6369086B1 (en) 1997-09-05 2002-04-09 Smithkline Beecham Corporation Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
WO1999033793A2 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Pro-medicaments qui sont des inhibiteurs de l'aspartyl protease
WO1999033792A2 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments des inhibiteurs de l'aspartyl-transferase
WO1999033795A1 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments de la classe des inhibiteurs d'aspartyle protease
WO1999033815A1 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Derives de sulfamide utilises comme precurseurs d'inhibiteurs de l'aspartyl protease
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
WO2014046617A1 (fr) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions et méthodes de traitement du cancer
US20220275368A1 (en) * 2019-08-12 2022-09-01 Interna Technologies B.V. New treatments involving mirna-193a

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. NM_005030.6
"Methods in Molecular Biology", vol. 248, 2004, HUMANA PRESS, article "Antibody Engineering: Methods and Protocols"
"Monoclonal Antibodies: A Manual of Techniques", 1987, CRC PRESS
"NCBI Genbank", Database accession no. NP_001017915.1
"NCBI Gene", Database accession no. 10769
"Polymorphism in Pharmaceutical Solids", 1995, MARCEL DEKKER
"Uniprot", Database accession no. Q9NYY3
BOSS ET AL.: "Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised in E", NUCLEIC ACIDS RESEARCH, 1984
CLARCKSON ET AL.: "Making antibody fragments using phage display libraries", NATURE, 1991
COKOL ET AL., FINDING NUCLEAR LOCALIZATION SIGNALS, EMBO REPORTS, 2000
E. L. ELIELS. H. WILENL. N. MANDER: "Stereochemistry of Organic Compounds", 1994, WILEY- INTERSCIENCE
GOODMANGILMAN: "The Pharmacological Basis of Therapeutics", 1992, MCGRAW-HILL, INT., article "Biotransformation of Drugs", pages: 13 - 15
HALEBLIAN, J PHARM SCI, vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288
HARLOWLANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOUR LABORATORY
HARLOWLANE: "Using Antibodies: A Laboratory Manual", 1999, COLD SPRING HARBOUR LABORATORY
KOHLER ET AL.: "Continuous cultures of fused cells secreting antibody of predefined specificity.", NATURE, 1975
KOLMAR: "Alternative binding proteins: Biological activity and therapeutic potential of cystine-knot miniproteins", FEBS JOURNAL, 2008
N. H. HARTSHORNEA. STUART: "Crystals and the Polarizing Microscope", 1970
O. ALMARSSONM. J. ZAWOROTKO, CHEM COMMUN, vol. 17, 2004, pages 1889 - 1896
SILVERMAN ET AL.: "Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains", NATURE BIOTECHNOLOGY, 2005
STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
STUMPP ET AL.: "DARPins: a new generation of protein therapeutics", DRUG DISCOVERY TODAY, 2008

Similar Documents

Publication Publication Date Title
US12286413B2 (en) Compounds and methods for treating cancer
JP2022050493A (ja) 癌を治療する方法における使用のための毛細血管拡張性運動失調症の変異したＲａｄ３関連タンパク質キナーゼ（ＡＴＲ）の阻害剤
US20150057335A1 (en) Novel fusion genes identified in lung cancer
US20100297109A1 (en) Methods for inhibiting fascin
KR20140019770A (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
JP2012502954A (ja) 癌治療のための方法および組成物
Winkler et al. Prosurvival function of the cellular apoptosis susceptibility/importin‐α1 transport cycle is repressed by p53 in liver cancer
Zhang et al. A novel PHD-finger protein 14/KIF4A complex overexpressed in lung cancer is involved in cell mitosis regulation and tumorigenesis
WO2014033136A1 (fr) Composés aminohétéroaryles en tant qu'inhibiteurs de mth1
Lin et al. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer
US20120094843A1 (en) Detecting and treating breast cancer resistance to egfr inhibitors
US10443054B2 (en) Methods for identifying and treating invasive/metastatic breast cancers
Brocardo et al. Adenomatous polyposis coli protein regulates the cellular response to DNA replication stress
US20130296188A1 (en) Targeting metabolic enzymes in human cancer
Zhu et al. Circular RNA circATM binds PARP1 to suppress Wnt/β-catenin signaling and induce cell cycle arrest in gastric cancer cells
WO2026013165A1 (fr) Association d'un inhibiteur de ship2 et d'un inhibiteur de plk1 destinée à être utilisée dans le traitement du cancer
Zhang et al. Transmembrane protein 45A regulates the proliferation, migration, and invasion of glioma cells through nuclear factor kappa-B
Wang et al. FANCA facilitates G1/S cell cycle advancement, proliferation, migration and invasion in gastric cancer: FANCA’s role in G1/S cell cycle progression and beyond in GC
Dabsan et al. Cytosolic and endoplasmic reticulum chaperones inhibit wt-p53 to increase cancer cells' survival by refluxing ER-proteins to the cytosol
US20240197738A1 (en) Compound 7ai in treating ewing sarcoma by inhibiting otud7a
CN118064581A (zh) 氟达拉滨作为nat10新型抑制剂和在治疗卵巢癌中的应用
US20080305102A1 (en) Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer
Ordóñez et al. Targeting sarcomas: therapeutic targets and their rational
EP3240540B1 (fr) Inhibiteurs de hdac1,2 et méthodes d'utilisation de ces dernières
Li et al. Comprehensive analytical approach identifies a subtype of CTCF+ tumor-associated neutrophils associated with CRC development and as a biomarker for immunotherapy